Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth

08/13/19

~ Richard S. Kollender Appointed to Chief Operating Officer ~ ~ Robert Lutz Promoted to Chief Financial Officer ~ ~ David Gill Appointed to Board of Directors ~ DUBLIN, Ireland and TREVOSE, Pa. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global...

Read More
Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update

07/31/19

~ KEVEYIS ® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS ® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV™ (levoketoconazole) Progressing with Top-Line Data Anticipated at the End of...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth

Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Upcoming Events